Associated Papers
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Protocol optimization of a targeted sequencing panel for genomic profiling of bronchoalveolar lavage fluid in lung cancer.
Sather CL et al.
Cancer Medicine, 2023
37587851 (PubMed )
Supplement: CAM4-12-17632-s002.xlsx › S8.HighCoverageVariantsExpPanel
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
37445722 (PubMed )
Supplement: ijms-24-10545-s001.zip › PTPN11_paper_supplementary_tables_25042023.pdf
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Lee MS et al.
Cancer Research and Treatment, 2017
Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.
Miao L et al.
Bmc Cancer, 2014
Collagen recognition and transmembrane signalling by discoidin domain receptors.
Carafoli F et al.
Biochimica Et Biophysica Acta, 2013
New targetable oncogenes in non-small-cell lung cancer.
Oxnard GR et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2013
Identification of driver mutations in lung cancer: first step in personalized cancer.
Planchard D
Targeted Oncology, 2013
DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients.
Sasaki H et al.
Oncology Letters, 2012
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS et al.
Cancer Discovery, 2011
Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.
Ford CE et al.
British Journal of Cancer, 2007
Select a paper to view details